Top 10 PBS earners face higher bar

Posted 2 August 2022 AM

There was strong growth in the top PBS earners for the second quarter of 2022, but one drug stood out in particular.

Sanofi's Dupixent, used to treat asthma, eczema, atopic dermatitis, and nasal polyps, joined the list in tenth spot after its pre-rebate reimbursement on the R/PBS almost tripled. In Q2 2021 it earned $16.3 million, while in Q2 2022 it brought in $46.0 million.

To see the whole article, please login